Details for New Drug Application (NDA): 213879
✉ Email this page to a colleague
NDA 213879 describes DABIGATRAN ETEXILATE MESYLATE, which is a drug marketed by Alembic, Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and MSN, and is included in five NDAs. It is available from nine suppliers. Additional details are available on the DABIGATRAN ETEXILATE MESYLATE profile page.
The generic ingredient in DABIGATRAN ETEXILATE MESYLATE is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the dabigatran etexilate mesylate profile page.
The generic ingredient in DABIGATRAN ETEXILATE MESYLATE is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the dabigatran etexilate mesylate profile page.
Summary for 213879
| Tradename: | DABIGATRAN ETEXILATE MESYLATE |
| Applicant: | Msn |
| Ingredient: | dabigatran etexilate mesylate |
| Patents: | 0 |
Pharmacology for NDA: 213879
| Mechanism of Action | Thrombin Inhibitors |
Medical Subject Heading (MeSH) Categories for 213879
Suppliers and Packaging for NDA: 213879
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DABIGATRAN ETEXILATE MESYLATE | dabigatran etexilate mesylate | CAPSULE;ORAL | 213879 | ANDA | AvKARE | 42291-033 | 42291-033-60 | 60 CAPSULE in 1 BOTTLE (42291-033-60) |
| DABIGATRAN ETEXILATE MESYLATE | dabigatran etexilate mesylate | CAPSULE;ORAL | 213879 | ANDA | AvKARE | 42291-034 | 42291-034-60 | 60 CAPSULE in 1 BOTTLE (42291-034-60) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 75MG BASE | ||||
| Approval Date: | May 22, 2024 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 150MG BASE | ||||
| Approval Date: | May 22, 2024 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 110MG BASE | ||||
| Approval Date: | Aug 12, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
